Drug intelligence / Profile preview

MDX-214

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MDX-214 is a discontinued bispecific (bifunctional) monoclonal antibody developed by Medarex. It was engineered to simultaneously target the epidermal growth factor receptor (EGFR, erbB1) on tumor cells and the CD89 (IgA Fc receptor) on immune effector cells, such as neutrophils and monocytes. The therapeutic intent was to recruit and activate these effector cells to destroy EGFR-expressing cancer cells via antibody-dependent cellular cytotoxicity (ADCC). MDX-214 reached Phase I/II clinical development for the treatment of various EGFR-positive solid tumors and neoplasms before its development was terminated.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)FCAR (Fc alpha receptor I)

Beyond the preview

Go deeper on MDX-214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDX-214.

Explore the full profile